Cullinan therapeutics provides corporate update and reports fourth quarter and full year 2024 financial results

Initial clinical data from global phase 1 study of cln-978 in systemic lupus erythematosus (sle) expected in q4 2025; cln-978 remains the first and only development-stage cd19 t cell engager in an autoimmune disease clinical trial in the u.s. zipalertinib pivotal phase 2b study met primary endpoint; full results mid-year 2025 and nda submission planned h2 2025, pending regulatory discussions cash and investments of $606.9 million as of december 31, 2024, continues to provide runway into 2028 cambridge, mass., feb. 27, 2025 (globe newswire) -- cullinan therapeutics, inc. (nasdaq: cgem; “cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended december 31, 2024.
CGEM Ratings Summary
CGEM Quant Ranking